News Summary: 5 more countries OK Pfizer's Xeljanz
(AP) - NEW APPROVALS: Five more countries will allow sales of Pfizer Inc.'s new twice-a-day pill for controlling rheumatoid arthritis, Xeljanz: Russia, Argentina, Kuwait, United Arab Emirates and Switzerland.
THE MARKET: Nearly 24 million people worldwide suffer from rheumatoid arthritis, a painful, often disabling immune disorder.
THE COMPETITION: Xeljanz could win patients away from pricey, injected biologic drugs approved for multiple immune disorders, including Enbrel, Humira and Remicade. They cost roughly $2,500 a month, compared to just over $2,000 for Xeljanz. It's heavily advertised in the U.S., where it was launched in November, but has dangerous potential side effects.
(Copyright 2013 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.)